Moglie Le Quintrec

List of Publications by Year
in descending order

41 papers	3,926 citations	218677 26 h-index	265206 42 g-index
44 all docs	44 docs citations	44 times ranked	3704 citing authors

#	Article	IF	Citations
1	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International, 2012, 82, 454-464.	5.2	454
2	Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nature Genetics, 2013, 45, 531-536.	21.4	419
3	Endothelium structure and function in kidney health and disease. Nature Reviews Nephrology, 2019, 15, 87-108.	9.6	292
4	Clinical Features of Anti-Factor H Autoantibodyâ€“Associated Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2010, 21, 2180-2187.	6.1	247
5	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney International, 2020, 98, 1549-1558.	5.2	213
6	New insights into postrenal transplant hemolytic uremic syndrome. Nature Reviews Nephrology, 2011, 7, 23-35.	9.6	169
7	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naÃ¯ve to complement inhibitor treatment. Kidney International, 2020, 97, 1287-1296.	5.2	123
8	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathyâ€“associated C3 glomerulopathy. Blood, 2017, 129, 1437-1447.	1.4	120
9	Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches. Seminars in Thrombosis and Hemostasis, 2014, 40, 444-464.	2.7	117
10	Antiâ€“Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases. Journal of Immunology, 2015, 194, 5129-5138.	0.8	99
11	Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. American Journal of Kidney Diseases, 2018, 72, 84-92.	1.9	94
12	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney International, 2017, 92, 1232-1241.	5.2	93
13	Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy. American Journal of Kidney Diseases, 2015, 65, 484-489.	1.9	87
14	Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood, 2021, 137, 2438-2449.	1.4	87
15	IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). Kidney International, 2020, 98, 1568-1577.	5.2	85
16	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2017, 28, 1603-1613.	6.1	83
17	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2019, 30, 2449-2463.	6.1	81
18	Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplantation Reviews, 2013, 27, 117-125.	2.9	74

#	Article	IF	Citations
19	Atypical and secondary hemolytic uremic syndromes have a distinct presentation andÂnoÂcommon genetic risk factors. Kidney International, 2019, 95, 1443-1452.	5.2	74
20	The Complement System and Antibody-Mediated Transplant Rejection. Journal of Immunology, 2015, 195, 5525-5531.	0.8	67
21	Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. Kidney International, 2021, 100, 1240-1249.	5.2	51
22	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Frontiers in Immunology, 2018, 9, 2260.	4.8	42
23	Targeting the complement cascade: novel treatments coming down the pike. Kidney International, 2016, 90, 746-752.	5.2	41
24	A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney International, 2017, 92, 876-887.	5.2	35
25	Genetics of hemolytic uremic syndromes. Presse Medicale, 2012, 41, e105-e114.	1.9	28
26	Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney International, 2020, 98, 1135-1148.	5.2	28
27	Dynapaenia and sarcopaenia in chronic haemodialysis patients: do muscle weakness and atrophy similarly influence poor outcome?. Nephrology Dialysis Transplantation, 2020, 36, 1908-1918.	0.7	21
28	Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney International, 2016, 90, 109-122.	5.2	16
29	C5b9 Deposition in Glomerular Capillaries Is Associated With Poor Kidney Allograft Survival in Antibody-Mediated Rejection. Frontiers in Immunology, 2019, 10, 235.	4.8	14
30	Distribution of de novo Donor-Specific Antibody Subclasses Quantified by Mass Spectrometry: High IgG3 Proportion Is Associated With Antibody-Mediated Rejection Occurrence and Severity. Frontiers in Immunology, 2020, 11, 919.	4.8	13
31	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. Kidney International Reports, 2021, 6, 746-754.	0.8	8
32	Clinical Utility of Biochemical Markers for the Prediction of COVID-19â^'Related Mortality in Kidney Transplant Recipients. Kidney International Reports, 2021, 6, 2689-2693.	0.8	8
33	Combined Liver-Kidney Transplantation With Preformed Antiâ€“human Leukocyte Antigen Donor-Specific Antibodies. Kidney International Reports, 2020, 5, 2202-2211.	0.8	6
34	The COVID-19 Pandemic Led to a Small Increase in Changed Mentality Regarding Infection Risk without Any Change in Willingness to Be Vaccinated in Chronic Diseases Patients. Journal of Clinical Medicine, 2021, 10, 3967.	2.4	6
35	IgG3 donorâ€“specific antibodies with a proinflammatory glycosylation profile may be associated with the risk of antibody-mediated rejection after kidney transplantation. American Journal of Transplantation, 2022, 22, 865-875.	4.7	6
36	Stricturing Crohnâ€™s disease-like colitis in a patient treated with belatacept. World Journal of Gastroenterology, 2017, 23, 8660-8665.	3.3	5

#	Article	IF	Citations
37	Incisional hernia repair after kidney transplantation in a tertiary high-volume center: outcomes from a 10-year retrospective cohort study. International Urology and Nephrology, 2022, 54, 525-531.	1.4	3
38	Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome. Journal of Nephrology, 2021, , 1.	2.0	2
39	Estimation of residual renal function using betaâ€trace protein: Impact of dialysis procedures. Artificial Organs, 2020, 44, 647-654.	1.9	1
40	Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report. Clinical Rheumatology, 2018, 37, 1119-1122.	2.2	0
41	In Reply to â€˜Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathyâ€™. American Journal of Kidney Diseases, 2018, 72, 906-907.	1.9	0